SIVA Health – a pragmatic co-innovation approach for the benefit of chronic cough patients – a Bayer inside perspective complemented with the view of a co-founder

Aus terminlichen Gründen wurde der Vortrag vom 19.06. auf den 04.09.2024 verschoben.

https://sanofi.zoom.us/meeting/register/tJYldeCppj0sH9yaRyRvugvsxXTM139d00C-

(Nach der Registrierung über den Link erhalten Sie die Zugangsdaten zu der Veranstaltung)

In the course of the drug development program of Eliapixant, a multi indication drug candidate in midstage clinical development, Bayer experimented with a co-innovation approach to improve current standard of care in cough diagnostics and helped founding SIVA Health.
Main topic of the presentation will be the rollercoaster ride during Ideation, Proof-of concept, development, Clinical Validation and finally a dramatic game changer and exit strategy.
Co-Founders of SIVA Health will provide their perspective of the past years and shine a light on the status quo and near future path.  

Wir freuen uns auf Ihre Teilnahme.
Dr. Reinhold Rößler
Dr. Frank Kramer